Compare · ABBV vs PCSA
ABBV vs PCSA
Side-by-side comparison of AbbVie Inc. (ABBV) and Processa Pharmaceuticals Inc. (PCSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PCSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $393.06B, about 68383.4x PCSA ($5.7M).
- Over the past year, ABBV is up 20.0% and PCSA is down 68.1% - ABBV leads by 88.1 points.
- ABBV has been more active in the news (12 items in the past 4 weeks vs 10 for PCSA).
- ABBV has more recent analyst coverage (25 ratings vs 3 for PCSA).
- Company
- AbbVie Inc.
- Processa Pharmaceuticals Inc.
- Price
- $222.53+0.47%
- $2.10-7.28%
- Market cap
- $393.06B
- $5.7M
- 1M return
- +5.73%
- -30.00%
- 1Y return
- +19.98%
- -68.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 12
- 10
- Recent ratings
- 25
- 3
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Processa Pharmaceuticals Inc.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Latest ABBV
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
- FDA Approval for SKYRIZI issued to ABBVIE INC
- FDA Approval for SKYRIZI issued to ABBVIE INC
- Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
Latest PCSA
- Pres. Research & Development Young David bought $4,589 worth of shares (2,067 units at $2.22), increasing direct ownership by 12% to 19,198 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,892 worth of shares (2,654 units at $2.22), increasing direct ownership by 25% to 13,412 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,465 units at $2.22), increasing direct ownership by 25% to 12,435 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,065 worth of shares (1,831 units at $2.22), increasing direct ownership by 20% to 11,007 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,702 worth of shares (2,118 units at $2.22), increasing direct ownership by 22% to 11,958 units (SEC Form 4)
- Pres. Research & Development Young David bought $4,590 worth of shares (1,786 units at $2.57), increasing direct ownership by 12% to 17,131 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,890 worth of shares (2,292 units at $2.57), increasing direct ownership by 27% to 10,758 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,129 units at $2.57), increasing direct ownership by 27% to 9,970 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,066 worth of shares (1,582 units at $2.57), increasing direct ownership by 21% to 9,176 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,701 worth of shares (1,829 units at $2.57), increasing direct ownership by 23% to 9,840 units (SEC Form 4)